AstraZeneca to buy U.S. biotech CinCor for as much as $1.8 billion
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has agreed to acquire U.S. biotech CinCor Pharma Inc (NASDAQ:CINC) in a deal worth as much as $1.8 billion, as the...
Strong Buy
or
AstraZeneca News & Analysis
-
-
European stocks edge higher; German industrial production impresses
By Peter Nurse Investing.com - European stock markets edged higher Monday, with sentiment boosted by China’s decision to fully reopen its borders as well as stronger-than-expected German...
-
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 billion deal
(Reuters) – AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of...
-
Dow Jones Newswires: AstraZeneca agrees to buy U.S.-based CinCor in deal valued at $1.3 billion
The Anglo-Swedish pharma giant said that it will initiate a tender offer to acquire all of U.S.-listed clinical-stage biopharmaceutical company CinCor's CINC outstanding shares.
-
AstraZeneca to buy U.S.-based CinCor Pharma in deal valued at $1.3 billion
AstraZeneca to buy U.S.-based CinCor Pharma in deal valued at $1.3 billion
-
AstraZeneca's COVID drug Evusheld unlikely to neutralize newest variant, FDA says
The Food and Drug Administration late Friday said that AstraZeneca Plc's COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one...
-
Friday’s Top Analyst Upgrades and Downgrades: American Express, AstraZeneca, Coinbase, Comcast, Delta Air Lines, Marathon Oil, Microsoft, Target and More
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike,...
-
Diabetic Nephropathy Market Report (2022 to 2030) – AstraZeneca, Bayer AG, Merck & Co, Novartis AG and Sanofi
Pune, Jan. 06, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Diabetic Nephropathy Market by Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors,...
-
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
BMO Capital Markets initiated coverage on AstraZeneca Plc (NASDAQ: AZN) with an Outperform rating and a price target of $82. The analyst writes that AstraZeneca's growth and margin expansion...
-
: AstraZeneca started at outperform with $82 stock price target at BMO Capital
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
-
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding...
-
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
The European Commission has approved AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for metastatic...
-
AstraZeneca slips after Imfinzi falls short in cancer trial
By Geoffrey Smith Investing.com -- AstraZeneca (LON:AZN) stock slipped in morning trading in London on Monday, after the U.K.-Swedish pharma company said its Imfinzi drug had failed to...
-
AstraZeneca Drug Imfinzi Fails As Monotherapy In Metastatic Lung Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) announced topline data from the PEARL Phase 3 trial of Imfinzi (durvalumab) monotherapy versus platinum-based chemotherapy (investigator's choice) as a 1st-line...
-
Dow Jones Newswires: AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure
The recommendation covers heart failure with reduced ejection fraction--a measure of the amount of blood the heart's left ventricle pumps with each heartbeat.
-
Dow Jones Newswires: AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU
The Anglo-Swedish pharma giant said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and...
-
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza...
-
Amgen secures $28.3 billion deal to buy Horizon Therapeutics
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
-
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
AstraZeneca Plc (NASDAQ: AZN) reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd). The data showed encouraging and durable efficacy in...
-
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally...
-
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
AstraZeneca Plc (NASDAQ: AZN) shared updated data from the DESTINY-Breast03 Phase 3 trial evaluating Enhertu versus trastuzumab emtansine (T-DM1) in previously treated patients with...
-
AstraZeneca acquires biotech Neogene for $320M in bid to expand cancer treatments
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has signed a $320 million cash and debt deal to acquire bio-technology group Neogene Therapeutics, as the U.K. drugmaker looks...
-
AstraZeneca ADR Earnings, Revenue beat In Q3
Investing.com - AstraZeneca (LON:AZN) ADR reported third quarter {{erl-39111||earnings that beat analysts' expectations on Thursday and revenue that topped forecasts. The firm reported...
-
AstraZeneca raises 2022 earnings outlook after Q3 results beat estimates
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has raised its guidance for full-year income per share, citing strong returns in its third quarter, but warned that the outlook...
-
Chasing green goals, corporations push car fleet managers toward EVs
(This Aug 12 story corrects to read ALD will likely set (not ALD has set) a new goal, paragraph 4) By Nick Carey and Ben Klayman MACCLESFIELD, England (Reuters) - Large corporations are...
-
Sanofi Shares Slide After Trials of Potential Breast Cancer Drug Halted
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) shares slid on Wednesday after the French drugmaker announced that it will halt trials of a new treatment for patients battling...
-
Chasing green goals, corporations push car fleet managers toward EVs
By Nick Carey and Ben Klayman MACCLESFIELD, England (Reuters) - Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage...
-
AstraZeneca Earnings, Revenue beat In Q2
Investing.com - AstraZeneca (LON:AZN) reported on Friday second quarter {{erl-6565||earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca announced...
-
AstraZeneca ADR Earnings, Revenue beat In Q2
Investing.com - AstraZeneca (LON:AZN) ADR reported second quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
-
Oil Producers, Procter & Gamble, AstraZeneca: 3 Things to Watch
By Liz Moyer Investing.com -- Stocks notched a two-day rally as investors believe the Federal Reserve could slow the pace of interest rate increases after new data showed the economy slowed...
-
Stellantis, Tesla, AstraZeneca Fall Premarket; Exxon Mobil Rises
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, July 5th. Please refresh for updates. Tesla (NASDAQ:TSLA) stock fell 1.4% after the electric car manufacturer...
-
AstraZeneca Unveils $1.27B Purchase of U.S. Biotech Firm TeneoTwo
By Scott Kanowsky Investing.com -- AstraZeneca (NASDAQ:AZN) has announced that it plans to acquire U.S. oncology firm TeneoTwo in a deal worth up to $1.27B, as the British-based...
-
European Stocks Drop; Economic Activity Concerns Weigh
By Peter Nurse Investing.com - European stock markets edged lower Tuesday, with concerns about the region’s economic recovery diluting the positive start to the new month. By 04:20 AM ET...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 0.19%
Investing.com – U.K. equities were lower at the close on Wednesday, as losses in the Automobiles & Parts, Real Estate Investment Trusts REITs and Real Estate sectors propelled shares...
-
U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 1.45%
Investing.com – U.K. equities were higher at the close on Wednesday, as gains in the Industrial Metals & Mining, Oil & Gas Producers and Life Insurance/Assurance sectors propelled shares...
-
AstraZeneca Earnings, Revenue beat In Q1
Investing.com - AstraZeneca (LON:AZN) reported on Friday first quarter {{erl-6565||earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca announced...
-
AstraZeneca Tops Q1 EPS by $1.06
AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99...
-
AstraZeneca ADR Earnings, Revenue beat In Q1
Investing.com - AstraZeneca (LON:AZN) ADR reported first quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
-
Inflation and GDP in the Eurozone: 5 Key Factors this Friday on the Stock Market
By Laura Sanchez Investing.com - Today, investors focus on important macro data, such as eurozone inflation and GDP in different European countries. We will also keep an eye on the corporate...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 0.38%
Investing.com – U.K. equities were lower at the close on Thursday, as losses in the Automobiles & Parts, Household Goods & Home Construction and Life Insurance/Assurance sectors propelled...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 0.43%
Investing.com – U.K. equities were lower at the close on Monday, as losses in the Mining, Industrial Transportation and Fixed Line Telecommunications sectors propelled shares lower. At the...
-
U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 1.01%
Investing.com – U.K. equities were higher at the close on Tuesday, as gains in the Pharmaceuticals & Biotech, Automobiles & Parts and General Industrial sectors propelled shares higher. At...
-
AstraZeneca Earnings, Revenue beat In Q4
Investing.com - AstraZeneca (LON:AZN) reported on Thursday fourth quarter {{erl-6565||earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca announced...
-
COVID vaccines: African countries need to fix their distribution chains
Bringing vaccine manufacturing closer to Africa to speed up supply is important for building capacity in the region. Guerchom Ndebo/Getty ImagesSub-Saharan Africa still has too few vaccines...
-
Asian Stocks Down, Bets on Fed Interest Rate Hikes Continue Upward Trend
By Gina Lee Investing.com – Asia Pacific stocks were mostly down on Monday morning, while U.S. futures were down, as bets that the U.S. Federal Reserve will hike interest rates also weighed...
-
The Week Ahead
US jobsIn the week ending Jan 8, the advance figure for seasonally adjusted initial claims was 230 000, an increase of 23 000 from the previous week's unrevised level of 207 000. The 4-week...
-
S&P 500 hits record close as Omicron fears ebb
By Lewis Krauskopf, Medha Singh and Bansari Mayur Kamdar (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&P 500 marking a...
-
Oil rises around 2% on strong U.S. demand, upbeat Fed outlook
By Stephanie Kelly NEW YORK (Reuters) -Oil prices rose around 2% on Thursday, as record U.S. implied demand, falling crude stockpiles and an upbeat economic outlook from the Federal Reserve...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
